139 related articles for article (PubMed ID: 20878355)
1. Same data sources, different pooled analysis result: the ongoing uncertainty in the subgroup analysis of RAD51 135G/C polymorphism and breast cancer risk.
Lu PH; Li C; Zhou HY; Wang T; Chu CQ; Shen W; Tao GQ
Breast Cancer Res Treat; 2011 Jan; 125(1):299-300. PubMed ID: 20878355
[No Abstract] [Full Text] [Related]
2. RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects.
Sun H; Bai J; Chen F; Jin Y; Yu Y; Jin L; Fu S
Breast Cancer Res Treat; 2011 Jan; 125(1):157-61. PubMed ID: 20454923
[TBL] [Abstract][Full Text] [Related]
3. RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls.
Sekhar D; Pooja S; Kumar S; Rajender S
Sci Rep; 2015 Jun; 5():11588. PubMed ID: 26108708
[TBL] [Abstract][Full Text] [Related]
4. RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects.
Wang Z; Dong H; Fu Y; Ding H
Breast Cancer Res Treat; 2010 Dec; 124(3):765-9. PubMed ID: 20396943
[TBL] [Abstract][Full Text] [Related]
5. RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis.
Zhou GW; Hu J; Peng XD; Li Q
Breast Cancer Res Treat; 2011 Jan; 125(2):529-35. PubMed ID: 20623332
[TBL] [Abstract][Full Text] [Related]
6. RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies.
Gao LB; Pan XM; Li LJ; Liang WB; Zhu Y; Zhang LS; Wei YG; Tang M; Zhang L
Breast Cancer Res Treat; 2011 Feb; 125(3):827-35. PubMed ID: 20640595
[TBL] [Abstract][Full Text] [Related]
7. RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies.
Yu KD; Yang C; Fan L; Chen AX; Shao ZM
Breast Cancer Res Treat; 2011 Apr; 126(2):365-71. PubMed ID: 20461453
[TBL] [Abstract][Full Text] [Related]
8. Need for clarification of data in the recent meta-analysis about RAD51 135G>C polymorphism and breast cancer risk.
He XF; Su J; Zhang Y; Ding DP; Wang W; Liu Y
Breast Cancer Res Treat; 2011 Sep; 129(2):649-51; author reply 652-3. PubMed ID: 21537934
[No Abstract] [Full Text] [Related]
9. New conflicting results obtained in the subgroup analysis of RAD51 135G>C polymorphism and breast cancer risk.
Lu PH; Chen MB; Shen W; Li C; Wu MY; Tao GQ
Breast Cancer Res Treat; 2011 Feb; 126(1):265-6. PubMed ID: 21110082
[No Abstract] [Full Text] [Related]
10. Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis.
Economopoulos KP; Sergentanis TN
Breast Cancer Res Treat; 2010 Nov; 124(1):293-4. PubMed ID: 20686834
[No Abstract] [Full Text] [Related]
11. Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion.
Yu KD; Li B; Zhou Y; Shao ZM
Breast Cancer Res Treat; 2011 Jul; 128(1):297-9; author reply 300. PubMed ID: 21331620
[No Abstract] [Full Text] [Related]
12. RAD51 Gene 135G/C polymorphism and the risk of four types of common cancers: a meta-analysis.
Cheng D; Shi H; Zhang K; Yi L; Zhen G
Diagn Pathol; 2014 Jan; 9():18. PubMed ID: 24457040
[TBL] [Abstract][Full Text] [Related]
13. The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
Söderlund Leifler K; Asklid A; Fornander T; Stenmark Askmalm M
J Cancer Res Clin Oncol; 2015 May; 141(5):797-804. PubMed ID: 25354554
[TBL] [Abstract][Full Text] [Related]
14. Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis.
Zeng X; Zhang Y; Yang L; Xu H; Zhang T; An R; Zhu K
Medicine (Baltimore); 2018 Jun; 97(26):e11251. PubMed ID: 29952992
[TBL] [Abstract][Full Text] [Related]
15. The effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk among Caucasians: a meta-analysis.
Shi S; Qin L; Tian M; Xie M; Li X; Qi C; Yi X
Tumour Biol; 2014 Jun; 35(6):5797-804. PubMed ID: 24599673
[TBL] [Abstract][Full Text] [Related]
16. RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population.
Jara L; Acevedo ML; Blanco R; Castro VG; Bravo T; Gómez F; Waugh E; Peralta O; Cabrera E; Reyes JM; Ampuero S; González-Hormazábal P
Cancer Genet Cytogenet; 2007 Oct; 178(1):65-9. PubMed ID: 17889711
[TBL] [Abstract][Full Text] [Related]
17. MTRR A66G polymorphism and breast cancer risk: a meta-analysis.
Hu J; Zhou GW; Wang N; Wang YJ
Breast Cancer Res Treat; 2010 Dec; 124(3):779-84. PubMed ID: 20411324
[TBL] [Abstract][Full Text] [Related]
18. No association of the TGF-β1 29T/C polymorphism with breast cancer risk in Caucasian and Asian populations: evidence from a meta-analysis involving 55,841 subjects.
Alqumber MA; Dar SA; Haque S; Wahid M; Singh R; Akhter N
Asian Pac J Cancer Prev; 2014; 15(20):8725-34. PubMed ID: 25374198
[TBL] [Abstract][Full Text] [Related]
19. Association between the RAD51 135 G>C polymorphism and risk of cancer: a meta-analysis of 19,068 cases and 22,630 controls.
Wang W; Li JL; He XF; Li AP; Cai YL; Xu N; Sun SM; Wu BY
PLoS One; 2013; 8(9):e75153. PubMed ID: 24040396
[TBL] [Abstract][Full Text] [Related]
20. Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls.
Zhang BB; Wang DG; Xuan C; Sun GL; Deng KF
Fam Cancer; 2014 Dec; 13(4):515-26. PubMed ID: 24859942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
